Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies

The CD39 selective antibody inhibits CD39 enzyme activity, which solves the immunosuppression problem caused by overexpression of CD39 in the tumor environment, enhances the function of immune cells, improves the killing ability of cancer cells, and provides a new therapeutic strategy.

CN118978594APending Publication Date: 2024-11-19TRISHULA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410622919.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-07-31
Filing Date
2018-07-30
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Overexpression of CD39 in the tumor environment leads to immunosuppression, promoting tumor growth and metastasis. The prior art is difficult to effectively regulate its activity and affect the effect of cancer treatment.

Method used

Develop antibodies that selectively bind to CD39 to inhibit the enzymatic activity of CD39, and specifically bind to the extracellular domain of CD39, reducing the production of adenosine, thereby affecting the function of immune cells.

Benefits of technology

Effectively inhibit the enzyme activity of CD39, enhance the function of immune cells, especially the activity of T cells, reduce tumor immune escape, improve the killing ability of cancer cells, and provide potential therapeutic strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978594A_ABST
    Figure CN118978594A_ABST
Patent Text Reader

Abstract

The present invention provides antibodies that selectively bind to CD39 and isomers and homologues thereof, and compositions comprising the antibodies. The invention also provides methods of using the antibodies, such as therapeutic and diagnostic methods.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of CN201880064027.3. Related applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 539,527, filed on July 31, 2017, which is incorporated herein by reference in its entirety. Field of the Invention

[0002] The present invention provides antibodies with binding specificity for CD39 and compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The present invention also provides methods of using the anti-CD39 antibodies for therapeutic and diagnostic purposes. Background of the Invention

[0003] CD39 is an integral membrane protein that hydrolyzes ATP phosphate to generate ADP and AMP. Human CD39 is a 510 amino acid protein with 7 possible N-linked glycosylation sites, 11 cysteine ​​residues, and 2 transmembrane regions. Structurally, it is characterized by two transmembrane domains, a small cytoplasmic domain containing NH2- and COOH-terminal segments, and a large extracellular hydrophobic domain composed of 5 highly conserved domains, called apyrase conserved regions (ACRs) 1 to 5, which are crucial for the enzyme's catabolic activity. CD39 becomes catalytically active when localized on the cell surface, and its glycosylation is important for protein folding, membrane targeting, and enzyme activity.

[0004] CD39 is constitutively expressed in the spleen, thymus, lung, and placenta, and in these tissues, it is primarily associated with endothelial cells and immune cell populations such as B cells, natural killer (NK) cells, dendritic cells, Langerhans cells, monocytes, macrophages, mesangial cells, neutrophils, and regulatory T cells (Tregs). Because CD39, along with other enzymes, degrades ATP, ADP, and AMP into adenosine, CD39 can be considered an immune switch that converts ATP-driven pro-inflammatory immune cell activity to an anti-inflammatory state mediated by adenosine.

[0005] In the tumor environment, cancer and immune cells can closely interact, creating an immunosuppressive environment by releasing immunomodulatory factors that support tumor growth. CD39 expression is increased in many solid tumors (e.g., colorectal cancer, head and neck cancer, pancreatic cancer (Kunzli et al., Am J Physiol, 2006, 292:223-230), bladder cancer, brain cancer, breast cancer, gastric cancer, hepatocellular carcinoma, lung cancer, non-small cell lung cancer (Li et al., Oncoimmunology, 2017, 6:6), chronic lymphocytic leukemia (Pulte et al., Clin Lymphoma Myeloma Leuk, 2011, 11(4):367-372) and lymphoma, melanoma (Dzhandzhugazyan et al., FEBS Letters, 1998, 430:227-230), ovarian cancer, and prostate cancer), indicating that this enzyme is involved in the development and progression of malignancies. Modulators of CD39 may offer potential therapeutics for these cancer types.

[0006] The interaction between tumor cells and their microenvironment is important for tumor formation. CD39 can participate in tumor immune escape by inhibiting the activation, clonal expansion and homing of tumor-specific T cells, thereby impairing the killing of tumor cells by effector T lymphocytes. In addition to these immunoregulatory roles, CD39 can directly regulate cancer cell growth, differentiation, invasion, migration, metastasis and angiogenesis. CD39 is important for the initiation of angiogenesis and the progression of angiogenesis. CD39 on vascular distribution mediates the angiogenic process in mouse models of melanoma, lung and liver malignancies.

[0007] Modulators of CD39 activity may also provide potential therapeutic agents for the treatment of CD39 conditions including, but not limited to, autoimmune diseases and infections. Specifically, modulators of CD39 activity may provide potential therapeutic agents for diseases such as, for example, but not limited to, celiac disease (Cook et al., American Academy of Allergy, Asthma & Immunology, 2017, Article in Press), colitis (Longhi et al., JCI Insight. 2017, 2(9)), thrombotic diseases (Marcus et al., Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 1:9-16), HIV infection (zur Wiesch et al., Journal of Virology, 2011, Feb:1287-1297), HBV infection, HCV infection, as well as inflammatory bowel disease (Friedman et al. PNAS, 2009, 106, 39:16788-16793) and Crohn's disease (Bai et al., J Immunol, 2014, 3366-3377). Abstract

[0008] The present invention provides antibodies that selectively bind to CD39. In some embodiments, the antibodies bind to human CD39. In some embodiments, the antibodies also bind to homologs of human CD39.

[0009] In some embodiments, the antibody comprises at least one CDR sequence defined by a consensus sequence provided herein. In some embodiments, the antibody comprises exemplary CDRs, V H or V L Sequence, heavy chain or light chain provided by the present invention, or its variant.In some aspects, the variant is a variant with one or more conservative amino acid substitutions.

[0010] The present invention also provides compositions and kits comprising the antibodies. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition can be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.

[0011] The present invention also provides methods of using the anti-CD39 antibodies provided herein. In some embodiments, the methods are therapeutic methods. In some embodiments, the methods are diagnostic methods. In some embodiments, the methods are analytical methods. In some embodiments, the methods are methods for purifying and / or quantifying CD39.

[0012] In some embodiments, the antibody is used to treat a disease or condition. In some aspects, the disease or condition is selected from cancer, autoimmune disease, and infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 A table showing the monovalent affinity of anti-huCD39 antibodies for the extracellular domain of recombinant human CD39 is provided. This table provides the binding kinetics of the interaction of anti-CD39 antibodies with the extracellular domain (ECD) of soluble recombinant human CD39 (ENTDP1) as determined by biomembrane interferometry (ForteBio Octet). Anti-CD39 antibodies were captured on an anti-human Fc sensor and exposed to recombinant human CD39 ECD at concentrations ranging from 10 to 300 nanomolar. The kinetic data were fully fitted to a simple 1:1 Langmuir binding model to generate association rate (kon) and dissociation rate (koff) values. The equilibrium dissociation constant (K D ) is calculated from the kon and koff values.

[0014] Figure 2A Figures A to E show that the human CD39 extracellular domain (ECD) inhibits the catabolism of ATP and ADP enzymes to Pi. Recombinant human CD39 at a final concentration of 10 nanomolar (A to D) or 5 nanomolar (E) was incubated with anti-CD39 IgG at a final concentration of 1 micromolar (A to D) or 0.25 micromolar (E) in 25mM Tris, 5mM CaCl2, pH 7.5 at room temperature for 2 hours. ATP (500 micromolar) was added to the reaction and incubated at 37°C for 60 minutes. Residual ATP levels in the reaction were determined using the CellTiter-Glo assay. Data values ​​are the average of 2 replicates.

[0015] Figure 2F Antibody binding to CHO cells expressing human or cynomolgus macaque CD39 is shown.

[0016] Figure 3 Antibody binding to MEL-28 (A) and 721 (B) cells is evaluated. Anti-CD39 antibodies (clone numbers are indicated in the figures) were titrated from 15 to 0.001 μg / ml. EC values ​​were calculated using GraphPad Prism software. 50 This figure is representative of three independent experiments.

[0017] Figure 4 Provided is the evaluation of antibodies that drive inhibition of ATP hydrolysis by CD39 on MEL-28 cells in a short-term ATP assay. Figure 4 A shows the results when anti-CD39 antibodies were compared to the nonspecific small molecule inhibitors POM-1 and ARL. Inhibition was determined by reducing phosphate release (Pi). Data are representative of at least 10 independent experiments. Anti-CD39 antibodies (clone numbers are indicated in the figure) were titrated from 15 to 0.001 μg / ml. IC50 values ​​were calculated using GraphPad Prism software, see Figure 4 B. Three independent experiments were performed.

[0018] Figure 5 Quantification is provided when MEL-28 cells are treated with a CD39 enzyme inhibitor. Figure 5 A shows the evaluation of ATP levels after incubation of MEL-28 cells with dose titration of anti-CD39 antibodies to inhibit enzyme activity. Figure 5 B provides the IC calculated using GrapPad Prism 50 At least three independent experiments were performed.

[0019] Figure 6 Shown are antibodies evaluated for overnight inhibition of CD39 enzymatic activity on MEL-28 cells. Figure 6 A shows anti-CD39 antibodies (each number represents a unique clone as indicated in the figure) titrated from 100 nM to 0.000610 nM. Figure 6 B provides the IC calculated using GraphPad Prism software 50 Values ​​represent three independent experiments.

[0020] Figure 7 The results of antibody binding tests on human and cynomolgus macaque primary B cells are shown. Figure 7 In A, anti-CD39 antibodies were titrated to purified B cells from healthy donors and detected with anti-human IgG-PE secondary antibody. 50 Calculated using GrapPad Prism software. Figure 7 In B, anti-CD39 antibodies were titrated to cynomolgus macaque PBMCs and detected using an anti-human IgG-PE secondary antibody. B cells were sorted using FlowJo software and ECs were calculated using GraphPad Prism. 50 .

[0021] Figure 8The evaluation of antibodies for inhibition of CD39 activity on primary human B cells is described. Anti-CD39 antibodies (each unique antibody clone number is indicated in the figure) were titrated from 100 to 0.00013 nM.

[0022] Figure 9 Provided is an evaluation of the inhibition of CD39 activity on primary human (a) and cynomolgus macaque (b) monocytes. Anti-CD39 antibodies (each number represents a unique antibody clone number as indicated in the figure) were titrated from 100 to 0.00013 nM and incubated with monocytes in the presence of ATP. Phosphate released by CD39 processing of ATP was quantified using a Malachite Green assay.

[0023] Figure 10 The anti-CD39 antibody and purified human CD4 + CD25 + CD127 dim Binding of Treg cells. Anti-CD39 antibodies were titrated to purified Treg cells from healthy donors and detected with anti-human IgG secondary antibodies. EC was calculated using GraphPad Prism software. 50 .

[0024] Figure 11 Results show the ability of antibodies to inhibit primary Treg CD39 activity. + CD25 + CD127 dim T regulatory cells were incubated with serially diluted anti-CD39 antibodies and tested for ATPase activity after addition of exogenous ATP. Free phosphate (Pi) was used as a readout for CD39 activity.

[0025] Figure 12 Treatment with anti-CD39 antibody was shown to increase IFNγ production in CD8 cells in response to CMV peptide in an antigen recall assay. + The percentage of T cells.

[0026] Figure 13 Compared to anti-CD39 antibodies and their variants generated based on Innate / Orega (BY-40v9) and Igenica (9-8B), the antibodies showed a significant difference in expression of MEL-28 ( Figure 13 A) and human monocytes ( Figure 13 B) Evaluation of inhibition of CD39 activity on CD39. Anti-CD39 antibodies were titrated as indicated and incubated in the presence of ATP. Phosphate released by CD39 processing of ATP was quantified using the malachite green assay.

[0027] Figures 14A to 14GExamples of antibodies are provided. Figure 14A Examples of antibodies are provided that bind to soluble recombinant CD39 ECD and cellular CD39 but do not inhibit ATPase activity and do not compete with cellular inhibitors for binding to ECD inhibitors. Figure 14B Examples of antibodies are provided that have limited ability to inhibit the ATPase activity of both soluble recombinant and cellular CD39 and that belong to a separate bin from other cellular CD39 inhibitors. Figure 14C Examples of antibodies are provided that inhibit the ATPase activity of soluble recombinant CD39 ECD but not cellular CD39 and that belong to a separate bin from other CD39 ECD inhibitors. Figure 14D Examples of antibodies that inhibit the ATPase activity of the ECD and cellular CD39 and that belong to separate bins from other CD39 ECD and / or cellular inhibitors are provided. Figure 14E Examples of inhibitory antibodies that make different contacts with CD39 are provided. Figure 14E There are two tables, Table 1 and Table 2. Table 1 provides examples of inhibitory antibodies that make different contacts with CD39. Table 2 provides examples of inhibitory antibodies that bind to critical but different contact residues of CD39. Figure 14F and Figure 14G FACS plots are provided highlighting the importance of certain human CD39 residues.

[0028] Figure 15 Shown that anti-CD39 antibodies inhibit 75% to 90% CD39. Anti-CD39 antibodies (100 nanomoles), isotype control antibodies (100 nanomoles) or ARL (200 micromoles) were incubated with MEL-28 cells endogenously expressing human CD39 for 2 hours. ATP was then added and the EnzChek kinetic Pi detection assay was used to monitor the rate at which CD39 hydrolyzes ATP to Pi. The initial enzyme rate (v0) was determined by the Pi linear region to the time curve within the first 15 minutes after adding ATP. Each value is the mean value of 3 replicates.

[0029] 16A to 16B The CD39 inhibitor 29872 is shown to be not a competitive inhibitor because it inhibits V max inhibition.

[0030] Figure 17 It was shown that anti-CD39 antibodies can induce internalization of CD39 on cynomolgus monkey monocytes.

[0031] Figure 18A comparison of the Kabat and Chothia numbering systems for CDR-H1 is shown. Adapted from Martin ACR (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Dübel (Eds.), Antibody Engineering vol. 2 (pp. 33-51). Springer-Verlag, Berlin Heidelberg.

[0032] Figure 19 Anti-CD39 antibodies were shown to increase stimulated CD4 + and CD8 + T cell proliferation.

[0033] Figure 20 Anti-CD39 antibodies were shown to increase the secretion of INF-γ, TNF-α, and IL-2 by stimulated PBMCs.

[0034] Figure 21 Anti-CD39 antibodies were shown to increase the secretion of INF-γ, TNF-α, IL-2, and IL-1β by stimulated PBMCs.

[0035] Figure 22 It was shown that CD39 inhibition resulted in ATP accumulation and blocked adenosine production. Detailed Description of the Invention definition

[0036] Unless otherwise defined, all technical terms, descriptions, and other scientific terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present invention pertains. In many cases, commonly understood terms are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not be construed as representing a difference from what is commonly understood in the art. The techniques and procedures described or referred to herein are generally understood by those skilled in the art and are commonly employed using conventional methods, such as, for example, the widely used molecular cloning methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Where appropriate, methods involving the use of commercially available kits and reagents are generally performed according to manufacturer-defined protocols and / or parameters, unless otherwise specified.

[0037] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0038] The term "about" refers to and encompasses the indicated value and ranges above and below that value. In certain embodiments, the term "about" refers to the specified value ±10%, ±5%, or ±1%. In certain embodiments, the term "about" refers to the specified value ± one standard deviation of that value.

[0039] The term "combinations thereof" includes every possible combination of the elements to which the term refers.

[0040] The terms "CD39" and "CD39 antigen" and "Cluster of Differentiation 39" are used interchangeably herein. CD39 is also known as extracellular nucleoside triphosphate diphosphohydrolase 1 (gene: ENTPD1; protein: NTPDase1, see www.ncbi.nlm.nih.gov / gene / 953). CD39 has also been referred to as ATPDase and SPG64. Each of these terms is used interchangeably. Unless otherwise indicated, the terms include any variants, isoforms, and species homologs of human CD39 that are naturally expressed by cells or expressed by cells transfected with the CD39 gene. In some embodiments, the CD39 protein comprises murine CD39. In some embodiments, the CD39 protein comprises cynomolgus CD39.

[0041] The term "immunoglobulin" refers to a class of structurally related proteins that typically comprise two pairs of polypeptide chains: a pair of light (L) chains and a pair of heavy (H) chains. In an "intact immunoglobulin," all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been described in detail. See, for example, Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (V H ) and heavy chain constant region (C H The heavy chain constant region generally contains three domains C H1 、C H2 and C H3Each light chain generally comprises a light chain variable region (V L ) and the light chain constant region. The light chain constant region generally comprises a domain (abbreviated as C L ).

[0042] The term "antibody" describes an immunoglobulin molecule and is used in its broadest sense in the present invention. Antibodies specifically include intact antibodies (e.g., intact immunoglobulins) and antibody fragments. Antibodies contain at least one antigen binding domain. An example of an antigen binding domain is a V H -V L The antigen-binding domain formed by the dimer. "CD39 antibody," "anti-CD39 antibody," "CD39 Ab," "CD39-specific antibody," or "anti-CD39 Ab" refers to an antibody as described herein that specifically binds to the antigen CD39. In some embodiments, the antibody binds to the extracellular domain of CD39.

[0043] V H and V L The V domains can be further subdivided into hypervariable regions ("hypervariable regions (HVRs)" also called "complementarity determining regions (CDRs)") interspersed with more conserved regions. The more conserved regions are called framework regions (FRs). H and V L Typically, the antibody comprises three CDRs and four FRs arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDRs are involved in antigen binding and confer antigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, which is incorporated herein by reference in its entirety.

[0044] The light chains of any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domains.

[0045] The heavy chains of any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. IgG and IgA classes are further divided into subclasses based on sequence differences and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0046] The amino acid sequence boundaries of a CDR can be determined by one of ordinary skill in the art using any of several known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikanie et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme), each of which is incorporated by reference in its entirety.

[0047] The positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 identified by the Kabat and Chothia schemes are provided in Table 1. For CDR-H1, the residue numbering is provided using both the Kabat and Chothia numbering schemes. Figure 1 A comparison of the kappa and Chosia numbering schemes for CDR-H1 is provided. See Martin (2010), supra.

[0048] Unless otherwise indicated, the numbering scheme used to identify specific CDRs in the present invention is the kappa / Choissiya numbering scheme. When the residues covered by these two numbering schemes differ, the numbering scheme will be indicated as kappa or Chosia. Table 1. Residues in CDRs according to the Kappa and Chosia numbering schemes CDR Kabat Chothia L1 L24-L34 L24-L34 L2 L50-L56 L50-L56 L3 L89-L97 L89-L97 H1 (Kaba number) H31-H35B H26-H32 or H34* H1 (Kossia number) H31-H35 H26-H32 H2 H50-H65 H52-H56 H3 H95-H102 H95-H102 *When numbering using the Kabat numbering convention, the C-terminus of CDR-H1 will differ between H32 and H34 depending on the length of the CDR, e.g. Figure 1 shown.

[0049] When referring to residues in the antibody heavy chain constant region, the "EU numbering scheme" (e.g., as reported by Kabat et al., supra) is generally used. Unless otherwise indicated, the EU numbering scheme is used to refer to residues in the antibody heavy chain constant region described herein.

[0050] "Antibody fragments" comprise a portion of an intact antibody, such as the antigen-binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab')2 fragments, Fab' fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0051] An "Fv" fragment comprises a non-covalently linked dimer of one heavy- and one light-chain variable domain.

[0052] A "Fab" fragment contains, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain of the heavy chain (C H1 Fab fragments can be generated, for example, by papain digestion of full-length antibodies.

[0053] "F(ab')2" fragments contain two Fab' fragments connected by a disulfide bond near the hinge region. F(ab')2 fragments can be generated, for example, by pepsin digestion of intact antibodies. F(ab') fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

[0054] "Single-chain Fv" or "sFv" or "scFv" antibody fragments contain V H domain and V L Domain. V H and V L The connection is usually made by a peptide linker. See Plückthun A. (1994). Antibodies from Escherichia coli. In Rosenberg M. & Moore GP (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, which is incorporated herein by reference in its entirety. The "scFv-Fc" fragment comprises an scFv attached to an Fc domain. For example, the Fc domain can be attached to the C-terminus of the scFv. The Fc domain can then be used to determine the directionality of the variable domains in the scFv (i.e., V H -V L or V L -VH ) and V H or V L Any suitable Fc domain known in the art or described herein may be used.

[0055] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and bind to the same epitope, excluding variants that normally occur during the production of monoclonal antibodies. Such variants are generally present only in small quantities. Monoclonal antibodies are generally obtained by a process comprising selecting a single antibody from a plurality of antibodies. For example, the selection process can be to select a unique clone from a collection of a plurality of clones such as hybridoma clones, phage clones, yeast clones, bacterial clones or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity to the target ("affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0056] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0057] The "humanized" form of a non-human antibody refers to a chimeric antibody containing minimal sequences derived from a non-human antibody. A humanized antibody is typically a human immunoglobulin (recipient antibody) in which the residues of one or more CDRs are replaced with residues of one or more CDRs of a non-human antibody (donor antibody). The donor antibody may be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having the desired specificity, affinity, or biological effect. In some examples, the selected framework region residues of the recipient antibody are replaced with residues of the corresponding framework region of the donor antibody. Humanized antibodies may also include residues that are not present in the recipient antibody or the donor antibody. Such modifications may be performed to further improve antibody function. For further details, see Jones et al., Nature, 1986, 321: 522-525; Riechmann et al., Nature, 1988, 332: 323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2: 593-596, each of which is incorporated herein by reference in its entirety.

[0058] A "human antibody" is an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell, or is derived from a non-human source utilizing human antibody repertoires or human antibody encoding sequences (e.g., obtained from a human source or de novo designed). Human antibodies specifically exclude humanized antibodies.

[0059] An "isolated antibody" refers to an antibody that has been separated from and / or recovered from components of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or non-proteinaceous substances. In some embodiments, the isolated antibody is purified to a degree sufficient to obtain at least 15 N-terminal or internal amino acid sequence residues, for example, by using a spinning cup sequencer. In some embodiments, the isolated antibody is purified to homogeneity as detected by Coomassie blue or silver staining under reducing or non-reducing conditions on gel electrophoresis (e.g., SDS-PAGE). Isolated antibodies include in situ antibodies within recombinant cells because at least one component of the natural environment of the antibody is absent. In some aspects, the isolated antibody is prepared by at least one purification step.

[0060] In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, the isolated antibody is provided in a solution comprising at least 85%, 90%, 95%, 98%, 99%, or 100% by weight of the antibody, the remainder of the weight comprising the weight of other solutes dissolved in the solvent.

[0061] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed in terms of the dissociation constant (K D ) represents. Affinity can be determined by conventional methods known in the art, including those described herein. Affinity can be determined using, for example, surface plasmon resonance (SPR) techniques such as The instrument is used for measurement.

[0062] With respect to antibody binding to a target molecule, the terms "specific binding" or "specifically binds to," "specific for," "selectively binds," and "selective for" a specific antigen (e.g., a polypeptide target) or an epitope of a specific antigen mean binding that is measurably distinct from nonspecific or selective interactions. Specific binding can be determined, for example, by measuring binding of the molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that is similar to the target, such as an excess of unlabeled target. In this case, specific binding is indicated if binding of the labeled target to the probe is competitively inhibited by excess unlabeled target.

[0063] The term "k d ”(sec -1 ) refers to the dissociation rate constant for a specific antibody-antigen interaction. This value is also called k 解离 value.

[0064] The term "k a ”(M -1 ×sec -1 ) refers to the association rate constant for a specific antibody-antigen interaction. This value is also called k 缔合 value.

[0065] The term "K D "(M) refers to the dissociation equilibrium constant of a specific antibody-antigen interaction. K D =k d / k a .

[0066] The term "K A ”(M -1 ) refers to the association equilibrium constant for a specific antibody-antigen interaction. K A =k a / k d .

[0067] An "affinity matured" antibody is an antibody that has one or more changes in one or more CDRs or FRs that result in an increase in the affinity of the antibody for its antigen compared to a parent antibody that does not have the changes. In one embodiment, an affinity matured antibody has nanomolar or picomolar affinities for the target antigen. Affinity matured antibodies can be generated using a variety of methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, which is incorporated herein by reference in its entirety) describes affinity mature antibodies derived from V H and V L Affinity maturation by domain replacement. Random mutagenesis of CDR and / or framework residues is described, for example, in: Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated herein by reference in its entirety.

[0068] In the present invention, when used in the context of two or more antibodies, the term "competes with" or "cross-competes with" means that two or more antibodies compete for binding to an antigen (e.g., CD39). In an exemplary assay, CD39 is coated on a plate and allowed to bind to a first antibody, after which a labeled second antibody is added. If the presence of the first antibody reduces the binding of the second antibody, the antibodies compete with each other. The term "competes with" also includes antibody combinations in which one antibody reduces the binding of another antibody, but no competition is observed when the antibodies are added in the opposite order. However, in some embodiments, the first and second antibodies inhibit the binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0069] The term "epitope" means a portion of an antigen that is capable of specific binding to an antibody. Epitopes often consist of surface accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics as well as specific charge characteristics. The difference between conformational and non-conformational epitopes is that binding to the former is lost in the presence of denaturing solvents, while the latter is not. An epitope may comprise amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding. The epitope to which an antibody binds can be determined using known epitope determination techniques, such as, for example, testing antibody binding to CD39 variants with different point mutations.

[0070] The percent "identity" between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve maximum percent sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, or CLUSTAL OMEGA software. One skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm needed to achieve maximum alignment over the entire length of the compared sequences.

[0071] "Conservative substitution" or "conservative amino acid substitution" refers to the replacement of one or more amino acids with one or more chemically or functionally similar amino acids. Conservative substitution tables provide similar amino acids that are well known in the art. Polypeptide sequences with such substitutions are known as "conservatively modified variants." Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the following amino acid groups are considered conservative substitutions for each other. acidic residues D and E basic residues K, R, and H Hydrophilic uncharged residues S, T, N, and Q Aliphatic uncharged residues G, A, V, L, and I Nonpolar uncharged residues C, M and P Aromatic residues F, Y and W Group 1 A, S, and T Group 2 D and E Group 3 N and Q Group 4 R and K Group 5 I, L, and M Group 6 F, Y and W Group A A and G Group B D and E Group C N and Q Group D R, K, and H Group E I, L, M, V Group F F, Y and W Group G S and T Group H C and M Other conservative substitutions can be found in, for example, Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) WH Freeman & Co., New York, NY. Antibodies generated by making one or more conservative amino acid residue substitutions in a parent antibody are termed "conservatively modified variants."

[0072] The term "amino acid" refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0073] In certain embodiments, "treating" or "treatment" of any disease or condition refers to ameliorating the disease or condition present in a subject. In another embodiment, "treating" or "treatment" includes ameliorating at least one physical parameter that may not be perceptible to the subject. In yet another embodiment, "treating" or "treatment" includes modulating the disease or condition, either physically (e.g., stabilizing perceptible symptoms) or physiologically (e.g., stabilizing physiological parameters) or both. In another embodiment, "treating" or "treatment" includes delaying the onset of the disease or condition.

[0074] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of an antibody or composition that is effective in treating a disease or disorder when administered to a subject.

[0075] As used herein, the terms "subject" or "patient" refer to a mammalian subject or patient. Exemplary subjects include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cattle, horses, camels, birds, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a cancer, autoimmune disease or condition, and / or infection that can be treated with the antibodies provided herein. In some embodiments, the subject is a human suspected of having a cancer, autoimmune disease or condition, and / or infection. 2. Antibodies

[0076] The present invention provides antibodies that selectively bind to human CD39, and nucleic acids encoding the antibodies. In some aspects, the antibodies selectively bind to the extracellular domain of human CD39.

[0077] In some embodiments, the antibody binds to a homolog of human CD39. In some aspects, the antibody binds to a homolog of human CD39 of a species selected from monkey, mouse, dog, cat, rat, cow, horse, goat, and sheep. In some aspects, the homolog is a cynomolgus macaque homolog. In some aspects, the homolog is a murine homolog.

[0078] In some embodiments, the antibody has one or more CDRs of a specific length with respect to the number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7, 8, or 9 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, 6, or 7 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 15, 16, 17, or 18 residues in length. In some embodiments, the Kabat / Chothia CDR-H3 of the antibody is 5, 6, 7, 8, 9, 10, 11, or 12 residues in length.

[0079] In some aspects, the antibody has a kappa / Chorsia CDR-L1 of 9, 10, 11, 12, 13, 14, 15, or 16 residues in length. In some aspects, the antibody has a kappa / Chorsia CDR-L2 of 6, 7, or 8 residues in length. In some aspects, the antibody has a kappa / Chorsia CDR-L3 of 8, 9, 10, 11, or 12 residues in length.

[0080] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.

[0081] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is IgA. In some aspects, the heavy chain is IgD. In some aspects, the heavy chain is IgE. In some aspects, the heavy chain is IgG. In some aspects, the heavy chain is IgM. In some aspects, the heavy chain is IgG1. In some aspects, the heavy chain is IgG2. In some aspects, the heavy chain is IgG3. In some aspects, the heavy chain is IgG4. In some aspects, the heavy chain is IgA1. In some aspects, the heavy chain is IgA2.

[0082] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab')2 fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is a scFv (sFv) fragment. In some aspects, the antibody fragment is a scFv-Fc fragment.

[0083] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0084] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.

[0085] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from the exemplary sequences provided herein.

[0086] In some aspects, the antibody inhibits CD39 from converting ATP to ADP and / or converting ADP to AMP. In some aspects, the antibody reduces the levels of phosphate, ADP, AMP, and / or adenosine, and / or increases the levels of ATP.

[0087] In some embodiments, the antibody increases stimulated CD4 + and CD8 + In some embodiments, the antibody increases the secretion of INF-γ, TNF-α, IL-2, and / or IL-1β by stimulated PBMCs.

[0088] In some embodiments, the antibody increases T effector cell function. In some embodiments, the antibody reduces the number of regulatory T cells in tissue or in circulation. In some embodiments, the antibody inhibits regulatory T cell activity. In some embodiments, the antibody increases B cell function. In some embodiments, the antibody increases antigen presenting cell function. In some embodiments, the antibody reduces or prevents the activation of phosphoantigen-specific T cells selected from MAIT cells and γδ T cells.

[0089] In some aspects, the decrease is about or less than a 10% decrease, about or less than a 20% decrease, about or less than a 30% decrease, about or less than a 40% decrease, about or less than a 50% decrease, about or less than a 60% decrease, about or less than a 70% decrease, about or less than a 80% decrease, about or less than a 90% decrease, or about a complete decrease. In some aspects, the increase is about or greater than a 10% increase, about or greater than a 20% increase, about or greater than a 30% increase, about or greater than a 40% increase, about or greater than a 50% increase, about or greater than a 60% increase, about or greater than a 70% increase, about or greater than an 80% increase, about or greater than a 90% increase, or a complete increase.

[0090] Because CD39 degrades ATP and ADP into adenosine, CD39 can be considered an immune switch that converts ATP-driven pro-inflammatory immune cell activity to an anti-inflammatory state mediated by adenosine. CD39 has a role in regulating the function of several immune cell types, including lymphocytes, neutrophils, monocytes / macrophages, dendritic cells, and endothelial cells, and switching this switch can have a significant impact on disease. For example, adenosine generation via CD39 is considered the primary mechanism of immunosuppressive function of regulatory T cells (Tregs).

[0091] The antibodies provided herein can be used to treat a variety of diseases and conditions, including cancer, autoimmune diseases, and infections. In some embodiments, the antibodies inhibit CD39 function on tumor cells. In some embodiments, the antibodies inhibit angiogenesis.

[0092] The frequency and cell surface expression of CD39+ Tregs are increased in some human cancers, and the importance of CD39+ Tregs in promoting tumor growth and metastasis has been demonstrated using several in vivo models. Immunohistochemical staining of normal and tumor tissues has shown that CD39 expression is significantly higher in several human cancer types than in normal tissues. In cancer specimens, CD39 is expressed by infiltrating lymphocytes, tumor stroma, and / or tumor cells. CD39 in cancer cells exhibits ATPase activity and generates adenosine. CD39+ cancer cells inhibit the proliferation of CD4 and CD8 T cells and the generation of cytotoxic effector CD8 T cells (CTLs) in a CD39- and adenosine-dependent manner. CDR-H3 sequences

[0093] In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94.In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 103. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 104. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 109.

[0094] In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-H3 sequence provided herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H3 sequences provided herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.2. V comprising exemplary CDRs H sequence

[0095] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more exemplary CDR-H sequences provided herein, and variants thereof. 2.2.1. V comprising exemplary Kabat CDRs H sequence

[0096] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises one or more kappa CDR-H sequences comprising, consisting of, or consisting essentially of one or more exemplary kappa CDR-H sequences provided herein, and variants thereof. 2.2.1.1. Kabat CDR-H3

[0097] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a CDR-H3 sequence of Kaba The CDR-H3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. In some aspects, the antibody comprises VH Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 85. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 103. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 104. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabbage CDR-H3 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO:109. 2.2.1.2. Kabat CDR-H2

[0098] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a CDR-H2 sequence of Kaba The CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 63 to SEQ ID NO: 81. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 63. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 64. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 65. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 66. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 67. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 68. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 69. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 70. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 71. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 72. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 73. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 74. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 75. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 79. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 80. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H2 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO:81. 2.2.1.3. Kabat CDR-H1

[0099] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a CDR-H1 sequence of Kaba The CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 25 to SEQ ID NO: 45. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 25. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 26. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 27. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 28. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 29. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 30. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 31. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 32. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 33. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 34. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 35. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 36. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 37. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 38. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 39. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 40. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 41. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 42. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 43. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabach CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 44. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Kabbage CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO:45. 2.2.1.4. Kabat CDR-H3 + Kabat CDR-H2

[0100] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Kaba CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109 and a Kaba CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 63 to SEQ ID NO: 81. In some aspects, the Kaba CDR-H3 sequence and the Kaba CDR-H2 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Kaba CDR-H3 and Kaba CDR-H2 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.1.5. Kabat CDR-H3 + Kabat CDR-H1

[0101] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Kaba CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109 and a Kaba CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 25 to SEQ ID NO: 45. In some aspects, the Kaba CDR-H3 sequence and the Kaba CDR-H1 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Kaba CDR-H3 and Kaba CDR-H1 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.1.6. Kabat CDR-H1 + Kabat CDR-H2

[0102] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Kaba CDR-H1 sequence and a Kaba CDR-H2 sequence, wherein the Kaba CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 25 to SEQ ID NO: 45, and the Kaba CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 63 to SEQ ID NO: 81. In some aspects, the Kaba CDR-H1 sequence and the Kaba CDR-H2 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Kabad CDR-H1 and Kabad CDR-H2 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.1.7. Kabat CDR-H1 + Kabat CDR-H2 + Kabat CDR-H3

[0103] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Kaba CDR-H1 sequence, a Kaba CDR-H2 sequence, and a Kaba CDR-H3 sequence, wherein the Kaba CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 25 to SEQ ID NO: 45, the Kaba CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 63 to SEQ ID NO: 81, and the Kaba CDR-H3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109. In some aspects, the Kaba CDR-H1 sequence, the Kaba CDR-H2 sequence, and the Kaba CDR-H3 sequence are all from a single exemplary V sequence provided herein. H For example, in some aspects, the Kabad CDR-H1, Kabad CDR-H2, and Kabad CDR-H3 are all derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence.

[0104] In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 25, a Kaba CDR-H2 sequence comprising SEQ ID NO: 63, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 27, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 84. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 85. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 25, a Kabach CDR-H2 sequence comprising SEQ ID NO: 66, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 27, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 28, a Kaba CDR-H2 sequence comprising SEQ ID NO: 67, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 29, a Kabach CDR-H2 sequence comprising SEQ ID NO: 68, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 64, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 31, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 88. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 32, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 89. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 90. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 34, a Kabach CDR-H2 sequence comprising SEQ ID NO: 72, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 91. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 92. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 35, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 92. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 36, a Kaba CDR-H2 sequence comprising SEQ ID NO: 72, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 73, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 37, a Kaba CDR-H2 sequence comprising SEQ ID NO: 74, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 75, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 94. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 39, a Kabach CDR-H2 sequence comprising SEQ ID NO: 76, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 95. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 40, a Kaba CDR-H2 sequence comprising SEQ ID NO: 76, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 96. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 39, a Kabach CDR-H2 sequence comprising SEQ ID NO: 76, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 94. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 97. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 41, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 98. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 41, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 99. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 41, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 100. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 75, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 101. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 42, a Kabach CDR-H2 sequence comprising SEQ ID NO: 78, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 102. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 75, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 103. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 43, a Kabach CDR-H2 sequence comprising SEQ ID NO: 79, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 104. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 103. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 106. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 38, a Kabach CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 107. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 44, a Kabach CDR-H2 sequence comprising SEQ ID NO: 80, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 108. In some aspects, the antibody comprises V H Sequence, the V H The sequences comprise: a Kaba CDR-H1 sequence comprising SEQ ID NO:45, a Kaba CDR-H2 sequence comprising SEQ ID NO:81, and a Kaba CDR-H3 sequence comprising SEQ ID NO:109.

[0105] In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 84. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 85. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 84. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 26, a Kabach CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 27, a Kabach CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 27, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 73, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 72, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 30, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 31, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 31, a Kaba CDR-H2 sequence comprising SEQ ID NO: 71, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 32, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 72, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 33, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 34, a Kaba CDR-H2 sequence comprising SEQ ID NO: 72, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 71, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 35, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises: a Kabach CDR-H1 sequence comprising SEQ ID NO: 35, a Kabach CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabach CDR-H3 sequence comprising SEQ ID NO: 90. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 70, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, the antibody comprises V H Sequence, the V H The sequences comprise: a Kaba CDR-H1 sequence comprising SEQ ID NO:39, a Kaba CDR-H2 sequence comprising SEQ ID NO:76, and a Kaba CDR-H3 sequence comprising SEQ ID NO:94. 2.2.1.8. V comprising exemplary Kabat CDRs H Sequence variants

[0106] In some embodiments, the present invention provides V H The sequences comprise variants of the exemplary kappa CDR-H3, CDR-H2, and / or CDR-H1 sequences provided herein.

[0107] In some aspects, the kappa CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an exemplary kappa CDR-H3 sequence provided herein. In some aspects, the kappa CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary kappa CDR-H3 sequences provided herein. In some aspects, the kappa CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary kappa CDR-H3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0108] In some aspects, the Kabah CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an exemplary Kabah CDR-H2 sequence provided herein. In some aspects, the Kabah CDR-H2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any exemplary Kabah CDR-H2 sequence provided herein. In some aspects, the Kabah CDR-H2 sequence comprises, consists of, or consists essentially of any exemplary Kabah CDR-H2 sequence provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0109] In some aspects, the Kaba CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an exemplary Kaba CDR-H1 sequence provided herein. In some aspects, the Kaba CDR-H1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any exemplary Kaba CDR-H1 sequence provided herein. In some aspects, the Kaba CDR-H1 sequence comprises, consists of, or consists essentially of any exemplary Kaba CDR-H1 sequence provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.2.2. V comprising exemplary Chothia CDRs H sequence

[0110] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises one or more Choshia CDR-H sequences comprising, consisting of, or consisting essentially of one or more exemplary Choshia CDR-H sequences provided herein, and variants thereof. 2.2.2.1. Chothia CDR-H3

[0111] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Choshia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cosmid CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cosmid CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 103. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 104. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Choshida CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 109. 2.2.2.2. Chothia CDR-H2

[0112] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Choshia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 46 to SEQ ID NO: 62. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 46. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 47. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 48. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 49. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 50. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 51. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 52. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 53. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 54. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 55. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 56. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 57. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 58. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 59. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 60. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 61. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Choshida CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 62. 2.2.2.3. Chothia CDR-H1

[0113] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 24. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 2. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 3. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 4. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 5. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 6. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 7. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 8. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 9. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 10. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 11. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 12. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 14. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 15. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 16. In some aspects, the antibody comprises a V H Sequence, the V HThe sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 17. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 18. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 20. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 21. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 22. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Cossia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 23. In some aspects, the antibody comprises a V H Sequence, the V H The sequence comprises a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 24. 2.2.2.4. Chothia CDR-H3 + Chothia CDR-H2

[0114] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Chosia CDR-H3 sequence and a Chosia CDR-H2 sequence, wherein the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109, and the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 46 to SEQ ID NO: 62. In some aspects, the Chosia CDR-H3 sequence and the Chosia CDR-H2 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Chosia CDR-H3 and Chosia CDR-H2 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.2.5. Chothia CDR-H3 + Chothia CDR-H1

[0115] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Chosia CDR-H3 sequence and a Chosia CDR-H1 sequence, wherein the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109, and the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 24. In some aspects, the Chosia CDR-H3 sequence and the Chosia CDR-H1 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Chosia CDR-H3 and Chosia CDR-H1 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.2.6. Chothia CDR-H1 + Chothia CDR-H2

[0116] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Chosia CDR-H1 sequence and a Chosia CDR-H2 sequence, wherein the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 24, and the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 46 to SEQ ID NO: 62. In some aspects, the Chosia CDR-H1 sequence and the Chosia CDR-H2 sequence are both derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Chosia CDR-H1 and Chosia CDR-H2 are both derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence. 2.2.2.7. Chothia CDR-H1 + Chothia CDR-H2 + Chothia CDR-H3

[0117] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Chosia CDR-H1 sequence, a Chosia CDR-H2 sequence, and a Chosia CDR-H3 sequence, wherein the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 24, the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 46 to SEQ ID NO: 62, and the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 82 to SEQ ID NO: 109. In some aspects, the Chosia CDR-H1 sequence, the Chosia CDR-H2 sequence, and the Chosia CDR-H3 sequence are all derived from a single exemplary V sequence provided herein. H For example, in some aspects, the Chosia CDR-H1, Chosia CDR-H2, and Chosia CDR-H3 are all derived from a single exemplary V sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. H sequence.

[0118] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 1, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 83. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 1, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 84. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 85. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 3, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 86. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 4, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chisiya CDR-H1 sequence comprising SEQ ID NO: 2, a Chisiya CDR-H2 sequence comprising SEQ ID NO: 46, and a Chisiya CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 5, a Chosia CDR-H2 sequence comprising SEQ ID NO: 49, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 6, a Chosia CDR-H2 sequence comprising SEQ ID NO: 50, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 82. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 7, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 8, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 88. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 9, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 89. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 90. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 11, a Chosia CDR-H2 sequence comprising SEQ ID NO: 54, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 91. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 12, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 92. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 13, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 93. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 92. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 14, a Chosia CDR-H2 sequence comprising SEQ ID NO: 54, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 15, a Chosia CDR-H2 sequence comprising SEQ ID NO: 55, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 16, a Chosia CDR-H2 sequence comprising SEQ ID NO: 56, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 94. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 18, a Chosia CDR-H2 sequence comprising SEQ ID NO: 57, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 95. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 19, a Chosia CDR-H2 sequence comprising SEQ ID NO: 57, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 96. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 21, a Chosia CDR-H2 sequence comprising SEQ ID NO: 57, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 94. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 97. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 22, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 98. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 22, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 99. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 22, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 100. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 101. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 59, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 102. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 103. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 23, a Chosia CDR-H2 sequence comprising SEQ ID NO: 60, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 104. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 105. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 106. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 51, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 107. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 17, a Chosia CDR-H2 sequence comprising SEQ ID NO: 61, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 108. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include: a Chothia CDR-H1 sequence comprising SEQ ID NO: 17, a Chothia CDR-H2 sequence comprising SEQ ID NO: 62, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 109.

[0119] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 83. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 84. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 85. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 86. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 84. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 2, a Chosia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 86. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 1, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 83. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 1, a Chosia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 86. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 93. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 55, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 54, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 8, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chisiya CDR-H1 sequence comprising SEQ ID NO: 8, a Chisiya CDR-H2 sequence comprising SEQ ID NO: 53, and a Chisiya CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 9, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 54, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 93. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 10, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 93. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 11, a Chosia CDR-H2 sequence comprising SEQ ID NO: 54, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 12, a Chosia CDR-H2 sequence comprising SEQ ID NO: 53, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 13, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 13, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 90. In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chosia CDR-H1 sequence comprising SEQ ID NO: 15, a Chosia CDR-H2 sequence comprising SEQ ID NO: 52, and a Chosia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises V H Sequence, the V HThe sequences comprise: a Chothia CDR-H1 sequence comprising SEQ ID NO: 18, a Chothia CDR-H2 sequence comprising SEQ ID NO: 57, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 94. 2.2.2.8. V comprising exemplary Chothia CDRs H Sequence variants

[0120] In some embodiments, the present invention provides V H The sequences comprise variants of the exemplary Chosia CDR-H3, CDR-H2, and / or CDR-H1 sequences provided herein.

[0121] In some aspects, the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an exemplary Chosia CDR-H3 sequence provided herein. In some aspects, the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any exemplary Chosia CDR-H3 sequence provided herein. In some aspects, the Chosia CDR-H3 sequence comprises, consists of, or consists essentially of any exemplary Chosia CDR-H3 sequence provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0122] In some aspects, the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an exemplary Chosia CDR-H2 sequence provided herein. In some aspects, the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any exemplary Chosia CDR-H2 sequence provided herein. In some aspects, the Chosia CDR-H2 sequence comprises, consists of, or consists essentially of any exemplary Chosia CDR-H2 sequence provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0123] In some aspects, the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an exemplary Chosia CDR-H1 sequence provided herein. In some aspects, the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any exemplary Chosia CDR-H1 sequence provided herein. In some aspects, the Chosia CDR-H1 sequence comprises, consists of, or consists essentially of any exemplary Chosia CDR-H1 sequence provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.3.V H sequence

[0124] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 179 to SEQ ID NO: 218. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 179. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 180. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 181. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 182. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 183. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 184. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 185. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 186. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 187. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 188. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 189. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 190. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 191. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 192. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 193. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of SEQ ID NO: 194. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 195. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 196. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 197. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 198. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 199. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 200. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 201. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 202. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of SEQ ID NO: 203. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 204. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 205. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 206. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 207. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 208. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 209. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 210. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 211. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 212. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 213. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 214. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 215. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 216. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 217. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises, consists of, or consists essentially of: SEQ ID NO:218. 2.3.1.V H Sequence variants

[0125] In some embodiments, the present invention provides V H The sequence comprises, consists of, or consists essentially of the following: The exemplary V H Sequence variants.

[0126] In some aspects, the V HThe sequence comprises, consists of, or consists essentially of the following: The exemplary V H In some aspects, the V H The sequence comprises, consists of, or consists essentially of: any of the exemplary V H Sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% identical.

[0127] In some embodiments, the V H The sequence comprises, consists of, or consists essentially of any of the exemplary V sequences provided herein with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. H In some aspects, the amino acid substitutions are conservative amino acid substitutions. CDR-L3 sequence

[0128] In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 141. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153.In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166.

[0129] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.5. V comprising exemplary CDRs L sequence

[0130] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more exemplary CDR-L sequences provided herein, and variants thereof. 2.5.1.CDR-L3

[0131] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 141. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. In some aspects, the antibody comprises a V L Sequence, the V LThe sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of: SEQ ID NO: 145. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. In some aspects, the antibody comprises a V L Sequence, the V LThe sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166. 2.5.2.CDR-L2

[0132] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 125 to SEQ ID NO: 140. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a V L Sequence, the VL The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 132. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 133. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 134. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 135. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 136. In some aspects, the antibody comprises a V L Sequence, the V LThe sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 137. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 138. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 139. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:140. 2.5.3.CDR-L1

[0133] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 110 to SEQ ID NO: 124. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 111. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a V L Sequence, the VL The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a V L Sequence, the V LThe sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a V L Sequence, the V L The sequence comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:124. 2.5.4.CDR-L3+CDR-L2

[0134] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence and a CDR-L2 sequence, wherein the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 141 to SEQ ID NO: 166, and the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 125 to SEQ ID NO: 140. In some aspects, both the CDR-L3 sequence and the CDR-L2 sequence are derived from a single exemplary V sequence provided herein. L For example, in some aspects, both the CDR-L3 and CDR-L2 are derived from a single exemplary V sequence selected from SEQ ID NO: 219 to SEQ ID NO: 248. L sequence. 2.5.5.CDR-L3+CDR-L1

[0135] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence and a CDR-L1 sequence, wherein the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 141 to SEQ ID NO: 166, and the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 110 to SEQ ID NO: 124. In some aspects, both the CDR-L3 sequence and the CDR-L1 sequence are derived from a single exemplary V sequence provided herein. L For example, in some aspects, both the CDR-L3 and CDR-L1 are derived from a single exemplary V sequence selected from SEQ ID NO: 219 to SEQ ID NO: 248. L sequence. 2.5.6.CDR-L1+CDR-L2

[0136] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence and a CDR-L2 sequence, wherein the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 110 to SEQ ID NO: 124, and the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 125 to SEQ ID NO: 140. In some aspects, both the CDR-L1 sequence and the CDR-L2 sequence are derived from a single exemplary V sequence provided herein. L For example, in some aspects, both the CDR-L1 and CDR-L2 are derived from a single exemplary V sequence selected from SEQ ID NO: 219 to SEQ ID NO: 248. L sequence. 2.5.7.CDR-L1+CDR-L2+CDR-L3

[0137] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence, wherein the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 110 to SEQ ID NO: 124, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 125 to SEQ ID NO: 140, and the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all derived from a single exemplary V sequence provided herein. L For example, in some aspects, the CDR-L1, CDR-L2, and CDR-L3 are all derived from a single exemplary V sequence selected from SEQ ID NO: 219 to SEQ ID NO: 248. L sequence.

[0138] In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 126, and a CDR-L3 sequence comprising SEQ ID NO: 142. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 127, and a CDR-L3 sequence comprising a sequence selected from SEQ ID NO: 142. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 143. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 112, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 144. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 126, and a CDR-L3 sequence comprising SEQ ID NO: 145. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 113, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence comprising SEQ ID NO: 146. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 114, a CDR-L2 sequence comprising SEQ ID NO: 130, and a CDR-L3 sequence comprising SEQ ID NO: 147. In some aspects, the antibody comprises V LSequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 149. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence comprising SEQ ID NO: 149. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 133, and a CDR-L3 sequence comprising SEQ ID NO: 150. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some aspects, the antibody comprises VL Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 136, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 153. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 154. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 156. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 157. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 122, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 158. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 159. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 160. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence comprising SEQ ID NO: 161. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 123, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence comprising SEQ ID NO: 162. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 163. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence comprising SEQ ID NO: 164. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 165. In some aspects, the antibody comprises V L Sequence, the VL The sequences include: a CDR-L1 sequence comprising SEQ ID NO: 124, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 166.

[0139] In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 144. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 144. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 126, and a CDR-L3 sequence comprising a sequence selected from SEQ ID NO: 144. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 150. In some aspects, the antibody comprises V L Sequence, the V L The sequences include: a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence comprising SEQ ID NO: 150. 2.5.8. V comprising exemplary CDR-L L Sequence variants

[0140] In some embodiments, the present invention provides V L The sequences comprise variants of the exemplary CDR-L3, CDR-L2, and / or CDR-L1 sequences provided herein.

[0141] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0142] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L2 sequence provided herein. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L2 sequences provided herein. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0143] In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L1 sequence provided herein. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L1 sequences provided herein. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.6.V L sequence

[0144] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of a sequence selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 219. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 220. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 221. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 222. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 223. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 224. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 225. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 226. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 227. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 228. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of SEQ ID NO: 229. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 230. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 231. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 232. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 233. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 234. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 235. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 236. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 237. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 238. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 239. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 240. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 241. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 242. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises, consists of, or consists essentially of: SEQ ID NO: 243. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 244. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 245. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 246. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO: 247. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises, consists of, or consists essentially of: SEQ ID NO:248. 2.6.1.V L Sequence variants

[0145] In some embodiments, the present invention provides V L The sequence comprises, consists of, or consists essentially of the following: The exemplary V L Sequence variants.

[0146] In some aspects, the V L The sequence comprises, consists of, or consists essentially of the following: The exemplary V L In some aspects, the V L The sequence comprises, consists of, or consists essentially of: any of the exemplary V L Sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.05% identical.

[0147] In some embodiments, the V LThe sequence comprises, consists of, or consists essentially of any of the exemplary V sequences provided herein with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. L In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.7. Pairs 2.7.1. CDR-H3-CDR-L3 Pairs

[0148] In some embodiments, the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is V H part, and the CDR-L3 sequence is V L part of.

[0149] In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:82 to SEQ ID NO:109, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:141 to SEQ ID NO:166.

[0150] In some aspects, the CDR-H3 sequence is SEQ ID NO: 82, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0151] In some aspects, the CDR-H3 sequence is SEQ ID NO: 83, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0152] In some aspects, the CDR-H3 sequence is SEQ ID NO: 84, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0153] In some aspects, the CDR-H3 sequence is SEQ ID NO: 85, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0154] In some aspects, the CDR-H3 sequence is SEQ ID NO: 86, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0155] In some aspects, the CDR-H3 sequence is SEQ ID NO: 87, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0156] In some aspects, the CDR-H3 sequence is SEQ ID NO: 88, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0157] In some aspects, the CDR-H3 sequence is SEQ ID NO: 89, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0158] In some aspects, the CDR-H3 sequence is SEQ ID NO: 90, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0159] In some aspects, the CDR-H3 sequence is SEQ ID NO: 91, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0160] In some aspects, the CDR-H3 sequence is SEQ ID NO: 92, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0161] In some aspects, the CDR-H3 sequence is SEQ ID NO: 93, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0162] In some aspects, the CDR-H3 sequence is SEQ ID NO: 94, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0163] In some aspects, the CDR-H3 sequence is SEQ ID NO: 95, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0164] In some aspects, the CDR-H3 sequence is SEQ ID NO: 96, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0165] In some aspects, the CDR-H3 sequence is SEQ ID NO: 97, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0166] In some aspects, the CDR-H3 sequence is SEQ ID NO: 98, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0167] In some aspects, the CDR-H3 sequence is SEQ ID NO: 99, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0168] In some aspects, the CDR-H3 sequence is SEQ ID NO: 100, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0169] In some aspects, the CDR-H3 sequence is SEQ ID NO: 101, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0170] In some aspects, the CDR-H3 sequence is SEQ ID NO: 102, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0171] In some aspects, the CDR-H3 sequence is SEQ ID NO: 103, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0172] In some aspects, the CDR-H3 sequence is SEQ ID NO: 104, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0173] In some aspects, the CDR-H3 sequence is SEQ ID NO: 105, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0174] In some aspects, the CDR-H3 sequence is SEQ ID NO: 106, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0175] In some aspects, the CDR-H3 sequence is SEQ ID NO: 107, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0176] In some aspects, the CDR-H3 sequence is SEQ ID NO: 108, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[0177] In some aspects, the CDR-H3 sequence is SEQ ID NO: 109, and the CDR-L3 sequence is selected from SEQ ID NO: 141 to SEQ ID NO: 166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 141. In some aspects, the CDR-L3 sequence is SEQ ID NO: 142. In some aspects, the CDR-L3 sequence is SEQ ID NO: 143. In some aspects, the CDR-L3 sequence is SEQ ID NO: 144. In some aspects, the CDR-L3 sequence is SEQ ID NO: 145. In some aspects, the CDR-L3 sequence is SEQ ID NO: 146. In some aspects, the CDR-L3 sequence is SEQ ID NO: 147. In some aspects, the CDR-L3 sequence is SEQ ID NO: 148. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR-L3 sequence is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR-L3 sequence is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166. 2.7.1.1. Variants of CDR-H3-CDR-L3 Pairs

[0178] In some embodiments, the CDR-H3-CDR-L3 pairs provided herein comprise variants of the exemplary CDR-H3 and / or CDR-L1 sequences provided herein.

[0179] In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-H3 sequence provided herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H3 sequences provided herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0180] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences provided herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.7.2.V H -V L right

[0181] In some embodiments, the antibody comprises V H Sequence and V L sequence.

[0182] In some aspects, the V H The sequence is V comprising, consisting of, or consisting essentially of H Sequences: SEQ ID NO: 179 to SEQ ID NO: 218, and the V L The sequence is V comprising, consisting of, or consisting essentially of L Sequences: SEQ ID NO:219 to SEQ ID NO:248.

[0183] In some aspects, the V H The sequence is SEQ ID NO: 179, and the VL The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0184] In some aspects, the V H The sequence is SEQ ID NO: 180, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0185] In some aspects, the V H The sequence is SEQ ID NO: 181, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0186] In some aspects, the V H The sequence is SEQ ID NO: 182, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0187] In some aspects, the V H The sequence is SEQ ID NO: 183, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0188] In some aspects, the V H The sequence is SEQ ID NO: 184, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0189] In some aspects, the V H The sequence is SEQ ID NO: 185, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0190] In some aspects, the V H The sequence is SEQ ID NO: 186, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0191] In some aspects, the V H The sequence is SEQ ID NO: 187, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0192] In some aspects, the V H The sequence is SEQ ID NO: 188, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0193] In some aspects, the V H The sequence is SEQ ID NO: 189, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0194] In some aspects, the V H The sequence is SEQ ID NO: 190, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0195] In some aspects, the V H The sequence is SEQ ID NO: 191, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0196] In some aspects, the V H The sequence is SEQ ID NO: 192, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0197] In some aspects, the V H The sequence is SEQ ID NO: 193, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0198] In some aspects, the V H The sequence is SEQ ID NO: 194, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0199] In some aspects, the V H The sequence is SEQ ID NO: 195, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0200] In some aspects, the V H The sequence is SEQ ID NO: 196, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0201] In some aspects, the V H The sequence is SEQ ID NO: 197, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0202] In some aspects, the V H The sequence is SEQ ID NO: 198, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0203] In some aspects, the V H The sequence is SEQ ID NO: 199, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0204] In some aspects, the V H The sequence is SEQ ID NO: 200, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0205] In some aspects, the V H The sequence is SEQ ID NO: 201, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0206] In some aspects, the V H The sequence is SEQ ID NO: 202, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0207] In some aspects, the V H The sequence is SEQ ID NO: 203, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0208] In some aspects, the V H The sequence is SEQ ID NO: 204, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0209] In some aspects, the V H The sequence is SEQ ID NO: 205, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0210] In some aspects, the V H The sequence is SEQ ID NO: 206, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0211] In some aspects, the V H The sequence is SEQ ID NO: 207, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0212] In some aspects, the V H The sequence is SEQ ID NO: 208, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0213] In some aspects, the V H The sequence is SEQ ID NO: 209, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0214] In some aspects, the V H The sequence is SEQ ID NO: 210, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0215] In some aspects, the V H The sequence is SEQ ID NO: 211, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0216] In some aspects, the V H The sequence is SEQ ID NO: 212, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0217] In some aspects, the V H The sequence is SEQ ID NO: 213, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0218] In some aspects, the V H The sequence is SEQ ID NO: 214, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0219] In some aspects, the V H The sequence is SEQ ID NO: 215, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0220] In some aspects, the V H The sequence is SEQ ID NO: 216, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V LThe sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0221] In some aspects, the V H The sequence is SEQ ID NO: 217, and the V L The sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V LThe sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V L The sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248.

[0222] In some aspects, the V H The sequence is SEQ ID NO: 218, and the V LThe sequence is selected from SEQ ID NO: 219 to SEQ ID NO: 248. In some aspects, the V L The sequence is SEQ ID NO: 219. In some aspects, the V L The sequence is SEQ ID NO: 220. In some aspects, the V L The sequence is SEQ ID NO: 221. In some aspects, the V L The sequence is SEQ ID NO: 222. In some aspects, the V L The sequence is SEQ ID NO: 223. In some aspects, the V L The sequence is SEQ ID NO: 224. In some aspects, the V L The sequence is SEQ ID NO: 225. In some aspects, the V L The sequence is SEQ ID NO: 226. In some aspects, the V L The sequence is SEQ ID NO: 227. In some aspects, the V L The sequence is SEQ ID NO: 228. In some aspects, the V L The sequence is SEQ ID NO: 229. In some aspects, the V L The sequence is SEQ ID NO: 230. In some aspects, the V L The sequence is SEQ ID NO: 231. In some aspects, the V L The sequence is SEQ ID NO: 232. In some aspects, the V L The sequence is SEQ ID NO: 233. In some aspects, the V L The sequence is SEQ ID NO: 234. In some aspects, the V L The sequence is SEQ ID NO: 235. In some aspects, the V L The sequence is SEQ ID NO: 236. In some aspects, the V L The sequence is SEQ ID NO: 237. In some aspects, the V L The sequence is SEQ ID NO: 238. In some aspects, the V L The sequence is SEQ ID NO: 239. In some aspects, the V L The sequence is SEQ ID NO: 240. In some aspects, the V L The sequence is SEQ ID NO: 241. In some aspects, the V LThe sequence is SEQ ID NO: 242. In some aspects, the V L The sequence is SEQ ID NO: 243. In some aspects, the V L The sequence is SEQ ID NO: 244. In some aspects, the V L The sequence is SEQ ID NO: 245. In some aspects, the V L The sequence is SEQ ID NO: 246. In some aspects, the V L The sequence is SEQ ID NO: 247. In some aspects, the V L The sequence is SEQ ID NO:248. 2.7.3.CDR-H1+CDR-H2+CDR-H3+CDR-L1+CDR-L2+CDR-L3

[0223] In some aspects, the antibody comprises V H Sequence and VL sequence, the V H The sequence comprises: a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 64, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 83, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 126, and a CDR-L3 sequence comprising SEQ ID NO: 142. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 27, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 84, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 64, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 85, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 64, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 86, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 127, and a CDR-L3 sequence comprising SEQ ID NO: 142. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 25, a Kaba CDR-H2 sequence comprising SEQ ID NO: 66, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 143. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 65, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 112, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 144. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The VL sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 126, and a CDR-L3 sequence comprising SEQ ID NO: 145. In some aspects, the antibody comprises a V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 28, a Kaba CDR-H2 sequence comprising SEQ ID NO: 67, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 113, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence comprising SEQ ID NO: 146. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 29, a Kaba CDR-H2 sequence comprising SEQ ID NO: 68, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 114, a CDR-L2 sequence comprising SEQ ID NO: 130, and a CDR-L3 sequence comprising SEQ ID NO: 147. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 26, a Kaba CDR-H2 sequence comprising SEQ ID NO: 64, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 82, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 125, and a CDR-L3 sequence comprising SEQ ID NO: 141. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 31, a Kaba CDR-H2 sequence comprising SEQ ID NO: 70, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 88, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 149. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 32, a Kaba CDR-H2 sequence comprising SEQ ID NO: 71, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 89, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 33, a Kaba CDR-H2 sequence comprising SEQ ID NO: 70, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 90, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence comprising SEQ ID NO: 149. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 34, a Kaba CDR-H2 sequence comprising SEQ ID NO: 72, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 91, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 71, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 92, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 35, a Kaba CDR-H2 sequence comprising SEQ ID NO: 70, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 93, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 133, and a CDR-L3 sequence comprising SEQ ID NO: 150. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 33, a Kaba CDR-H2 sequence comprising SEQ ID NO: 70, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 92, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 36, a Kaba CDR-H2 sequence comprising SEQ ID NO: 72, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 30, a Kaba CDR-H2 sequence comprising SEQ ID NO: 73, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 37, a Kaba CDR-H2 sequence comprising SEQ ID NO: 74, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 87, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 148. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 75, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 94, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The VL sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some aspects, the antibody comprises a V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 40, a Kaba CDR-H2 sequence comprising SEQ ID NO: 76, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 96, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 136, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 39, a Kaba CDR-H2 sequence comprising SEQ ID NO: 76, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 94, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 97, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 153. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 41, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 98, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 154. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 41, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 99, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 41, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 100, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 156. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 75, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 101, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 157. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 42, a Kaba CDR-H2 sequence comprising SEQ ID NO: 78, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 102, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 122, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 158. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 75, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 103, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 159. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 43, a Kaba CDR-H2 sequence comprising SEQ ID NO: 79, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 104, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 160. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 75, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 103, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence comprising SEQ ID NO: 161. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 105, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 123, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence comprising SEQ ID NO: 162. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 106, wherein the V L The sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 163. In some aspects, the antibody comprises V H Sequence and V L Sequence, the V H The sequence comprises: a Kaba CDR-H1 sequence comprising SEQ ID NO: 38, a Kaba CDR-H2 sequence comprising SEQ ID NO: 69, and a Kaba CDR-H3 sequence comprising SEQ ID NO: 107, wherein the V LThe sequence comprises: a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 ...

Claims

1. An antigen binding protein that specifically binds to human CD39 (hCD39) and is capable of doing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 of the following: a) Inhibit the binding of CD39 to ATP; b) inhibiting CD39 from converting ATP to ADP and / or ADP to AMP; c) reduce the affinity of CD39 for ATP or ADP; d) inhibiting or blocking the release of ADP or AMP from CD39; e) Block or inhibit the processivity of CD39; f) inhibit platelet aggregation; g) reducing the levels of phosphate, ADP, AMP, and / or adenosine, and / or increasing the levels of ATP; h) Increase T effector cell function; i) reduce the number of regulatory T cells in tissues or in circulation; j) inhibiting regulatory T cells or regulatory T cell activity; k) Increase B cell function; l) Increase antigen presenting cell function; m) inhibiting CD39 function on tumor cells; n) inhibiting the processing of at least one phospho-antigen from phosphorylated isoprenoids, phosphorylated vitamin B metabolites, and / or phosphorylated riboflavin; o) reducing or preventing the activation of phosphoantigen-specific T cells selected from MAIT cells and γδ T cells; p) inhibit angiogenesis; q) Increase stimulated CD4 + and CD8 + T cell proliferation; r) increasing the secretion of INF-γ, TNF-α, IL-2, and / or IL-1β by stimulated PBMCs.

2. The antigen-binding protein of claim 1, wherein the antigen-binding protein has 1, 2, 3, 4, 5, 6 or 7 of the following features: a) is a monoclonal antibody; b) is a human antibody, a humanized antibody, or a chimeric antibody; c) is a bispecific antibody, a multispecific antibody, a diabody, or a multivalent antibody; d) is of IgG1, IgG2, IgG3, IgG4, or IgM type; e) is an antigen-binding antibody fragment; f) is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, or a Fv fragment; and / or g) is a single-chain antibody, a single-domain antibody, or a nanobody.

3. A pharmaceutical composition comprising an effective amount of an antibody that binds to hCD39 and has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 of the following features: a) blocking or reducing the hydrolysis of ATP to ADP and / or the hydrolysis of ADP to AMP, as determined by at least one of: (i) a decrease in phosphate release (Pi), (ii) an increase in ATP levels, and (iii) a decrease in ADP, AMP, and / or adenosine levels; b) Increase T effector cell activity; c) inhibiting regulatory T cells or reducing regulatory T cell activity; d) reducing the number of regulatory T cells in tissues or in circulation; e) Increase B cell function; f) Increase antigen presenting cell function; g) inhibiting CD39 function on tumor cells; h) blocking or inhibiting processing of at least one phosphoantigen selected from the group consisting of phosphorylated isoprenoids, phosphorylated vitamin B metabolites, and phosphorylated riboflavin; i) reducing or preventing the activation of phosphoantigen-specific T cells selected from MAIT cells and γδ T cells; k) inhibiting angiogenesis; l) Reduced affinity for ATP and / or ADP; m) inhibiting the release of ADP or AMP from CD39; n) Block or inhibit the processivity of CD39; o) Inhibit platelet aggregation; p) Increase stimulated CD4 + and CD8 + T cell proliferation; r) increasing the secretion of INF-γ, TNF-α, IL-2, and / or IL-1β by stimulated PBMCs.

4. A pharmaceutical composition comprising the antigen-binding protein according to claim 1 or 2.

5. The pharmaceutical composition according to claim 4, further comprising an effective amount of at least one of the following: a) Anti-PD-1 antibodies, b) Anti-PD-L1 antibodies, c) anti-CD73 antibodies, d) anti-CD38 antibody, e) anti-A2A receptor antibodies, f) anti-A2B receptor antibodies, g) anti-A2A / A2B dual receptor antibody, or any combination thereof, or h) small molecule inhibitors, or a combination thereof.

6. The pharmaceutical composition according to claim 4 or 5, further comprising one or both of the following: a) antibodies that inhibit receptors or ligands, and / or b) antibodies to co-stimulatory receptors or ligands, or a combination thereof.

7. The pharmaceutical composition according to claim 6, in, (i) the inhibitory receptor or ligand is at least one of CTLA-4, PD-L2, LAG-3, Tim3, neuritin, BTLA, CECAM-1, CECAM-5, VISTA, LAIR1, CD160, 2B4, TGF-R, HHLA2, ILT2, ILT3, ILT4, HLA-G, HLA-C, and / or killer cell immunoglobulin-like receptor (KIR), and / or (ii) the co-stimulatory receptor or ligand is at least one of OX40, CD2, CD27, CDS, ICAM-1, LFA-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, and / or CD83. 8 . The pharmaceutical composition according to claim 7 , wherein the co-stimulatory receptor or ligand LFA-1 further comprises LFA-1 β chain CD18, and / or LFA-1 α chain CD11a.

9. The antigen binding protein of claim 1, wherein the antigen binding protein has one or more of the following characteristics: a) binds to a human CD39 polypeptide or a variant thereof with a KD of less than about 20 nM; b) binds to a cynomolgus monkey (cyno) CD39 polypeptide or a variant thereof with a KD of less than about 200 nM; c) binds to a murine CD39 polypeptide or a variant thereof with a KD of less than about 200 nM; or d) A combination of at least two of a), b) and c).

10. An antigen binding protein that competes with a reference antigen binding protein for binding to human CD39 or is capable of competing with a reference antigen binding protein for binding to human CD39, wherein the reference antigen binding protein is the antigen binding protein of claim 1.

11. An antigen binding protein that binds to human CD39 or is capable of competing with a reference antigen binding protein for binding to human CD39, wherein the reference antigen binding protein binds to an epitope at positions 143 to 158 or 274 to 277 of SEQ ID NO: 249 on the human CD39 polypeptide, including but not limited to D150, E153, R154 or N99 alone, or in combination with D150, E153, R154, or any combination thereof.

12. The antigen binding protein according to claim 10 or 11, wherein the antigen binding protein cross-competes with the reference antibody for binding to human CD39 or is capable of cross-competing with binding to human CD39.

13. The antigen binding protein of claim 1, comprising a human heavy chain constant region or fragment, or a variant thereof, wherein the constant region variant comprises up to 20 conservatively modified amino acid substitutions from any sequence shown in SEQ ID NO: 179 to SEQ ID NO:

218.

14. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and / or VL comprises 1, 2, 3, 4, 5 or 6 of the following: a) VHCDR1 having a sequence shown in SEQ ID NO: 1 to SEQ ID NO: 45, b) VHCDR2 having a sequence shown in SEQ ID NO: 46 to SEQ ID NO: 81, c) a VHCDR3 having a sequence shown in SEQ ID NO: 82 to SEQ ID NO: 109, d) VLCDR1 having a sequence shown in SEQ ID NO: 110 to SEQ ID NO: 124, e) VLCDR2 having a sequence shown in SEQ ID NO: 125 to SEQ ID NO: 140, and f) VLCDR3 having a sequence shown in SEQ ID NO:141 to SEQ ID NO:

166.

15. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: a) VHCDR1 having a sequence shown in SEQ ID NO: 1 to SEQ ID NO: 45, b) VHCDR2 having a sequence shown in SEQ ID NO: 46 to SEQ ID NO: 81, and c) a VHCDR3 having a sequence shown in SEQ ID NO: 82 to SEQ ID NO: 109; and The VL comprises: a) VLCDR1 having a sequence shown in SEQ ID NO: 110 to SEQ ID NO: 124, b) VLCDR2 having a sequence shown in SEQ ID NO: 125 to SEQ ID NO: 140, and c) VLCDR3 having a sequence shown in SEQ ID NO:141 to SEQ ID NO:

166.

16. An isolated nucleic acid encoding the antigen binding protein of claim 1, 14 or 15.

17. An expression vector comprising the nucleic acid of claim 16.

18. A prokaryotic or eukaryotic host cell comprising the vector of claim 17.

19. An oncolytic virus encoding the nucleic acid of claim 16 or 17.

20. A method for producing a recombinant protein, the method comprising the steps of expressing the nucleic acid of claim 16 in a prokaryotic or eukaryotic host cell, and recovering the protein from the cell or the cell culture supernatant.

21. A method for treating a subject suffering from cancer, chronic infection, or inflammatory disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising an effective amount of the antigen binding protein of claim 1 or the pharmaceutical composition of claim 3.

22. The method of claim 21, wherein the cancer is a solid cancer.

23. The method of claim 21, wherein the cancer is a hematological cancer.

24. A method for modulating immune system function in a subject in need thereof, the method comprising the following steps: contacting a population of immune cells of the subject with a pharmaceutical composition comprising an effective amount of the antigen binding protein of claim 1 under conditions such that the immune system is modulated.

25. A method of inducing or enhancing an immune response in a subject in need thereof, the method comprising the step of administering to the subject a pharmaceutical composition comprising an antigen binding protein, wherein the immune response is generated against a tumor antigen.

26. The method of claim 24 or 25, wherein the subject is a human subject.

27. The method of claim 25, wherein the antigen binding protein comprises a bispecific antibody or a composite antigen binding protein.

28. The method of claim 27, wherein the antigen binding protein, the bispecific antibody, or the composite antigen binding protein is administered in an amount sufficient to achieve 1, 2, 3, 4, 5, 6, or 7 of the following in the subject: a) reducing CD39 ATPase activity in target cell populations; b) reduce the suppression of effector T cell activity by regulatory T cells; c) reduce the levels of regulatory T cells; d) Activation of effector T cells; e) Induce or enhance the proliferation of effector T cells; f) inhibiting tumor growth; and / or g) Inducing tumor regression.

29. The method of claim 28, wherein the target cell population comprises T cells, B cells, monocytes, macrophages, dendritic cells, myeloid-derived suppressor cells, and / or tumor cells.

30. The method of claim 25, wherein the method further comprises one or more of the following: a) administration of chemotherapy; b) administering radiation therapy; and / or c) administering one or more additional therapeutic agents.

31. The method of claim 30, wherein the one or more additional therapeutic agents comprises one or more immunostimulants.

32. The method of claim 31, wherein the one or more immunostimulants comprise an antagonist of an inhibitory receptor of an immune cell.

33. The method of claim 32, wherein the inhibitory receptor is at least one of CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, Tim3, neurite factor, BTLA, CECAM-1, CECAM-5, VISTA, LAIR1, CD160, 2B4, TGF-R, and / or killer cell immunoglobulin-like receptor (KIR).

34. The method of claim 31, wherein the one or more immunostimulatory agents comprise an agonist of a co-stimulatory receptor of an immune cell.

35. The method of claim 34, wherein the co-stimulatory receptor is OX40, CD2, CD27, CDS, ICAM-1, LFA-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, or CD83 ligand.

36. The method of claim 35, wherein the co-stimulatory receptor or ligand LFA-1 further comprises LFA-1 β chain CD18 and / or LFA-1 α chain CD11a.

37. The method of claim 31, wherein the one or more immunostimulants comprise a cytokine.

38. The method of claim 37, wherein the cytokine is at least one of IL-2, IL-5, IL-7, IL-12, IL-15, and / or IL-21.

39. The method of claim 31, wherein the one or more immunostimulatory agents comprise an oncolytic virus.

40. The method of claim 39, wherein the oncolytic virus is herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, or maraba virus.

41. The method of claim 31, wherein the one or more immunostimulatory agents comprise chimeric antigen engineered T cells.

42. The method of claim 31, wherein the one or more immunostimulatory agents comprise bispecific or multispecific T cell directed antibodies.

43. The method of claim 25, wherein the one or more additional therapeutic agents comprises a trap of at least one immunosuppressant.

44. The method of claim 43, wherein the at least one immunosuppressive trap comprises at least one of an anti-TGF-β antibody, a TGFb receptor trap, an anti-IL-10 antibody and / or an anti-IL-10 receptor trap, and / or an anti-IL-35 antibody trap and / or an anti-IL-35 receptor trap.

45. The method of any one of claims 3-44, wherein administration of the pharmaceutical composition results in induction or enhancement of T effector cell proliferation, or modulation of I-κB and / or NF-κB in the T cells, or modulation of CD39 activity in the T cells, or T cell receptor-induced signaling in T effector cells, or a combination thereof.

46. ​​A method for screening a test compound, wherein the test compound comprises the antigen binding protein of claim 1 that is capable of inhibiting CD39 activity, the method comprising the following steps: contacting a test sample containing CD39 with a test compound; comparing the activity of the test sample with that of a control sample; By comparing the CD39 activity in the test sample with that in the control sample, the compound is shown to be a compound that inhibits CD39 activity.

47. The method of claim 46, wherein the control sample comprises a sample that has not been contacted with a test compound.

48. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), VH contains at least one of the following: a) VHCDR1 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO: 1 to SEQ ID NO: 45, b) a VHCDR2 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO: 46 to SEQ ID NO: 81, and c) a VHCDR3 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO: 82 to SEQ ID NO: 109; and VL contains at least one of the following: a) VLCDR1 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO: 110 to SEQ ID NO: 124, b) VLCDR2 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO: 125 to SEQ ID NO: 140, and c) VLCDR3 having an amino acid sequence that is at least 90% identical to the sequence shown in SEQ ID NO:141 to SEQ ID NO:

166.

49. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), VH contains at least one of the following: a) VHCDR1 having an amino acid sequence homologous to the sequences shown in SEQ ID NO: 1 to SEQ ID NO: 45, b) VHCDR2 having an amino acid sequence homologous to the sequence shown in SEQ ID NO:46 to SEQ ID NO:81, and c) VHCDR3 having an amino acid sequence homologous to the sequences shown in SEQ ID NO:82 to SEQ ID NO:109; and VL contains at least one of the following: a) VLCDR1 having an amino acid sequence homologous to the sequences shown in SEQ ID NO: 110 to SEQ ID NO: 124, b) VLCDR2 having an amino acid sequence homologous to the sequences shown in SEQ ID NO: 125 to SEQ ID NO: 140, and c) VLCDR3 having an amino acid sequence homologous to the sequences shown in SEQ ID NO:141 to SEQ ID NO:

166.

50. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain and a light chain, wherein the heavy chain comprises one or more molecules having a sequence consisting of one of the following: SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, or SEQ ID NO: 295, and the light chain comprises one or more molecules having a sequence consisting of one of the following: SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, or SEQ ID NO: 295 NO:258, SEQ ID NO:260, SEQ ID NO:262, SEQ ID NO:264, SEQ ID NO:266, SEQ ID NO:268, SEQ ID NO:270, SEQ ID NO:272, SEQ ID NO:274, SEQ ID NO:276, SEQ ID NO:278, SEQ ID NO:280, SEQ ID NO:282, SEQ ID NO:284, SEQ ID NO:286, SEQ ID NO:288, SEQ ID NO:290, SEQ ID NO:292, SEQ ID NO:294, or SEQ ID NO:

296.

51. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain and a light chain, a) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 255, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 256; b) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 257, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 258; c) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 259, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 260; d) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 261, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 262; e) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 263, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 264; f) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 265, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 266; g) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 267, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 268; h) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 269, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 270; i) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 271, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 272; j) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 273, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 274; k) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 275, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 276; 1) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 277, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 278; m) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 279, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 280; n) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 281, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 282; o) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 283, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 284; p) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 285, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 286; q) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 287, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 288; r) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 289, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 290; s) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 291, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 292; t) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 293, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO: 294; or u) the heavy chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO:295, and the light chain comprises one or more molecules, each molecule having a sequence consisting of SEQ ID NO:

296.

52. An isolated nucleic acid encoding the antigen binding protein of any one of claims 48-51.

53. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and / or VL comprises 1, 2, 3, 4, 5 or 6 of the following: a) a VHCDR1 sequence comprising: (i) From the consensus sequence SY-Δ 3 -M-Δ 5 The Kabat CDRH1 sequences defined in (SEQ ID NO: 25 to SEQ ID NO: 29 and SEQ ID NO: 44 to SEQ ID NO: 45), wherein Δ 3 is E, F, Q or Y, and Δ 5 is H or Y; (ii) From the consensus sequence θ 1 -θ 2 -θ 3 -IS defined Kabat CDR-H1 sequences (SEQ ID NO: 30 to SEQ ID NO: 37), wherein θ 1 is A, H, K, L, S or W; θ 2 is L, M, N, or T; and θ 3 is A or P; (iii) by consensus sequence η 1 -Y-η 3 -IS defined Kabat CDR-H1 sequences (SEQ ID NO: 38 to SEQ ID NO: 41), wherein n 1 is S, K, N or R, and η 3 is A or G; (iv) From the consensus sequence GYTF-Ω 5 -SY defined Chothia CDR-H1 sequences (SEQ ID NO: 1 to SEQ ID NO: 2, and SEQ ID NO: 4 to SEQ ID NO: 6), wherein Ω 5 is T, K, Q, F or V; (v) by the consensus sequence GGTF-ν 5 -ν 6 -Y defined Chothia CDR-H1 sequence (SEQ ID NO: 17 to SEQ ID NO: 22, and SEQ ID NO: 24), wherein v 5 is S, G or E, and ν 6 is S, K, R or S; or (vi) by the consensus sequence GGTF-κ 5 -κ 6 -κ 7 The Chothia CDR-H1 consensus sequences defined by 5 is S, Q, P or A; κ 6 is S, K, H, L, A, or W; and 7 is Y, L, T, N or M, b) a VHCDR2 sequence comprising: (i) By consensus sequence ε 1 -INP-ε 5- ε 6 -GST-ε 10 - Kabat CDR-H2 sequences defined by YAQKFQG (SEQ ID NO: 63 to SEQ ID NO: 66, and SEQ ID NO: 68), wherein ε 1 is K, S, R or V; ε 5 is L, R or S; 6 is G or V; and ε 10 is S or W; (ii) by consensus sequence GI-α 3 -α 4 -α 5 -α 6 - Kabat CDR-H2 sequences defined by GTANYAQKFQG (SEQ ID NO: 69 to SEQ ID NO: 72), wherein α 3 Is I or L, or does not exist; α 4 is P or absent; and α 5 is I, G, or R; and α 6 is A, F or G; (iii) By consensus sequence β 1 -IIP-β 5 -β 6 -G-β 8 - Kabat CDR-H2 sequences defined by ANYAQKFGQ (SEQ ID NO: 74, and SEQ ID NO: 76 to SEQ ID NO: 79), wherein β 1 is S or G; β 5 is I, E, S or T; β 6 is F, I, or S; and β 8 is I or T; (iv) By consensus sequence NP-ε 5- ε 6 -GST defined Chothia CDR-H2 sequences (SEQ ID NO: 46 to SEQ ID NO: 48), wherein ε 5 is L, R or S, and ε 6 is G or V; (v) By consensus sequence α 3 -α 4 -α 5 -α 6 -GTA defined Chothia CDR-H2 sequences (SEQ ID NO: 51 to SEQ ID NO: 54), wherein α 3 Is I or L, or does not exist; α 4 is P or absent; and α 5 is I, G, or R; and α 6 is A, F or G; or (vi) by consensus sequence IP-β 5 -β 6 -G-β 8 -A defined Chothia CDR-H2 sequences (SEQ ID NO: 56 to SEQ ID NO: 60), wherein β 5 is I, E, S or T; β 6 is F, I, or S; and β 8 is I or T, c) a VHCDR3 sequence comprising: (i) From the consensus sequence GKREGGTEYLRy 12 The CDR-H3 sequences defined in (SEQ ID NO: 82 to SEQ ID NO: 86), wherein y 12 is H, K, S, N or V; (ii) From the consensus sequence ESG-Φ 4 -YRDHRL-Ф 11 -V defined CDR-H3 sequences (SEQ ID NO:94 to SEQ ID NO:96), wherein Ф 4 is G or T, and Ф 11 is D or G; or (iii) From the consensus sequence GGAKYA-Э 7 -E 8 -E 9 - CDR-H3 sequences defined by GMDV (SEQ ID NO:87 to SEQ ID NO:93), wherein 7 is S, V, G or R; Э 8 is T, Q, K, G or R; and Э 9 is Y, H, L or W, d) a VLCDR1 sequence comprising: (i) From the consensus sequence φ 1 -AS-φ 4 -φ 5 -V-φ 7 -φ 8 -φ 9 -YLA defined CDR-L1 sequences (SEQ ID NO: 1101 to SEQ ID NO: 114), wherein φ 1 is E, K or R; φ 4 is Q or E; φ 5 is S or Y; φ 7 is S or A; φ 8 is S or Y; and φ 9 is D or S; (ii) By consensus sequence The defined CDR-L1 sequences (SEQ ID NO: 118, and SEQ ID NO: 120 to SEQ ID NO: 123), wherein is Q or Rl; is D or S; is I or V; is G or S; is N, R or S; is N, Y, or W; and is A or N; or (iii) From the consensus sequence KSS-Г 4 -SVL-Г 8 -S-G 10 - CDR-L1 sequences defined by NNKNYLA (SEQ ID NO: 115 to SEQ ID NO: 117), wherein Г 4 is Q, R or K; Г 8 is F or Y; and Г 10 is S or N, e) a VLCDR2 sequence comprising: (i) From the consensus sequence ψ 1 -AS-ψ 4 -R-ψ 6 -ψ 7 The CDR-L2 sequences defined in (SEQ ID NO: 125 to SEQ ID NO: 136), wherein ψ 1 is G or Y, ψ 4 is S or N; 6 is A or H; and ψ 7 is T, Y or N; (ii) by consensus sequence DAS-χ 4 - RAT defined CDR-L2 sequences (SEQ ID NO: 138 and SEQ ID NO: 139), wherein 4 is N or K; or (iii) By consensus sequence WASTR-σ 6 -S defined CDR-L2 sequence (SEQ ID NO: 131, and SEQ ID NO: 133 to SEQ ID NO: 134), wherein σ 6 is A, E, or Q, and f) a VLCDR3 sequence comprising: (i) From the consensus sequence QQY-π 4 -π 5 -π 6 -π 7 -T defined CDR-L3 sequences (SEQ ID NO: 141 to SEQ ID NO: 147), wherein π 4 is G, H or Y; π 5 is S, N, F, G or R; π 6 is S, Y, A, G, or R; and π 7 is P, I or L; (ii) From the consensus sequence QQ-λ 3 -λ 4 -λ 5 -λ 6 -PT defined CDR-L3 sequences (SEQ ID NO: 148 to SEQ ID NO: 150), wherein λ 3 is R, F, H, S, L, D, Y or V; 4 is S, V, T, G, L, Y or N; 5 is N, L, F, K, or V; and λ 6 is W, F, Y or L; (iii) From the consensus sequence QQY-ρ 3 -ρ 4 - WPLT defined CDR-L3 sequence (SEQ ID NO: 151 and SEQ ID NO: 152), wherein p 3 is N or L, and ρ 4 is N or L; or (iv) From the consensus sequence QQ-ω 3 -ω 4 -ω 5 -ω 6 -P-ω 8 -T defined CDR-L3 sequences (SEQ ID NO: 153 to SEQ ID NO: 156), wherein ω 3 is Y or F; ω 4 is Y or W; ω 5 is S, L, T or F; ω 6 is T, Y, or F; and ω 8 It is L or P.